21st.BIO Develops New Method for Scalable, Animal-Free Production of Essential Dairy Protein

21st.BIO has launched a new program to produce bovine alpha-lactalbumin (α-lac) using precision fermentation technology, aiming to make the essential dairy protein more accessible and affordable. The company has secured an exclusive license for a high-yield microbial strain developed by Novonesis, a biosolutions company. By optimizing the fermentation process for large-scale production, 21st.BIO hopes to overcome the traditional challenges associated with extracting α-lac from cow’s milk, which is costly and inefficient.

In addition to addressing supply challenges and sustainability concerns in the dairy industry, the program will support companies in various sectors by providing access to microbial strains, fermentation process development, scale-up assistance, and regulatory guidance. The move towards producing α-lac through fermentation not only opens up new markets beyond infant nutrition but also offers a more sustainable and efficient solution to meet the increasing global demand for dairy proteins. 21st.BIO's expansion into precision fermentation highlights the potential for this technology to bridge the impending protein supply gap, reduce strain on natural resources, and create a more resilient supply chain.